- Home
- LTRN vs GSIW Comparison
LTRN vs GSIW Comparison
Compare LTRN & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LTRN | GSIW |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 24.2M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LTRN | GSIW |
|---|---|---|
| Price | $1.93 | $16.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 121.4K | 21.4K |
| Earning Date | 05-14-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.05 |
| 52 Week High | $4.70 | $38.55 |
Technical Indicators
Market Signals| Indicator | LTRN | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 23.63 | 43.55 |
| Support Level | $1.11 | $14.84 |
| Resistance Level | $2.41 | $18.24 |
| Average True Range (ATR) | 0.20 | 1.61 |
| MACD | -0.02 | 0.48 |
| Stochastic Oscillator | 7.84 | 70.64 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
About GSIW Garden Stage Limited
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.